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Justice and surgical innovation: the case of robotic prostatectomy 
 





Surgical innovation promises improvements in healthcare, but it also raises ethical issues 
including risks of harm to patients, conflicts of interest and increased injustice in access to 
health care. In this paper, we focus on risks of injustice, and use a case study of robotic 
prostatectomy to identify features of surgical innovation that risk introducing or exacerbating 
injustices. Interpreting justice as encompassing matters of both efficiency and equity, we first 
examine questions relating to government decisions about whether to publicly fund access to 
innovative treatments. Here the case of robotic prostatectomy exemplifies the difficulty of 
accommodating healthcare priorities such as improving the health of marginalized groups. It 
also illustrates challenges with estimating the likely long-term costs and benefits of a new 
intervention, the difficulty of comparing outcomes of an innovative treatment to those of 
established treatments, and the further complexity associated with patient and surgeon 
preferences. Once the decision has been made to fund a new procedure, separate issues of 
justice arise at the level of providing care to individual patients. Here, the case of robotic 
prostatectomy exemplifies how features of surgical innovation, such as surgeon learning 
curves and the need for an adequate volume of cases at a treatment centre, can exacerbate 
injustices associated with treatment cost and the logistics of traveling for treatment. Drawing 
on our analysis, we conclude by making a number of recommendations for the just 











Surgical innovation can bring improvements in patient survival and quality of life, and 
sometimes improve the situation of those in marginalized groups.
1
 However, it can also pose 
ethical concerns. For example, patients may be subject to unacceptable risks of harm during 
the development of new devices or procedures; conflicts of interest can compromise surgical 
decision making; and innovation may lead to inequities such as a two-tiered treatment 
pathway, where patients who are already better off have greater access to cutting-edge 
treatments.
2
 To date, work on the ethics of surgical innovation has mainly focused on harms 
to patients and conflicts of interest. However, there are also important issues of justice to be 
examined.  For example, some features of surgical innovation present prima facie risks in 
terms of introducing or exacerbating unfair inequalities in health outcomes and health care 
access. For instance, surgical innovations tend to be high-cost and involve surgeon learning 
curves, which means that they require a sufficient volume of patients to remain cost-effective 
and safe. A high volume of patients, in turn, may only be possible in densely populated urban 
areas, where population health and health care access may already tend to be better than in 
rural and remote areas, as is the case in Australia. In this way, surgical innovations risk 
exacerbating unfair inequalities in health and health care access. In this paper, we examine 
such justice-related ethical issues as they arise in relation to surgical innovation. We aim to 
formulate recommendations to assist policy makers and regulators to avoid introducing or 
exacerbating injustices when making decisions regarding the development, uptake, funding 
and distribution of surgical innovations. 
 
We develop these recommendations by analyzing a case study: robotic laparoscopic 
prostatectomy (henceforth robotic prostatectomy). In this case, a new technology – a surgical 
robot – offers an alternative to the standard surgical treatments for prostate cancer: either a 
non-robotic laparoscopic procedure – laparoscopic prostatectomy – or an open prostatectomy. 
The case study enables us to explore how features of what is clearly an instance of surgical 
innovation,
3
 can exacerbate familiar injustices related to access to healthcare treatments. We 
find that such injustices can result from financial barriers (e.g. the new treatment is too 
expensive for some patients), geographical barriers (e.g. the new treatment is only available 
                                                 
1
A recent non-surgical example is the Indian invention, Swasthya Slate (health tablet), a 
revolutionary device that makes diagnostic tests with same-day results available to patients in 
remote regions. It was designed to improve antenatal services in rural India, and amongst 
other benefits it has reduced the mortality from pre-eclampsia in this marginalized 
population. See, Wunker, Stephen “How the swasthya slate is revolutionizing healthcare” 
Forbes Magazine 22
nd




 J. Johnson & W. Rogers. Innovative surgery: the ethical challenges. J Med Ethics 2011, 
DOI:10.1136/jme.2010.042150. 
3
 Part of the rationale for choosing to focus on a new technology rather than a new procedure, 
is that it represents an uncontentious case of surgical innovation. It thereby sidesteps 
questions of how to define surgical innovation, which are by no means straightforward.   
 
 3 
in certain centrally located hospitals) or social barriers (e.g. the new treatment depends upon 
the availability of social supports such as a carer during the postoperative period). 
 
We begin by outlining how robotic surgery was developed and diffused. Following this, we 
distinguish justice considerations at the health system level from those at the individual 
patient level, and explore each in turn. We conclude with a summary of the implications of 
our analysis for the uptake of innovative surgical treatments, and with recommendations for 




Case study: the history of robotic prostatectomy 
 
In 2000 the Food and Drug Administration (FDA) first approved for use in the United States 
a robot designed to perform surgery: the da Vinci® surgical system commercialized by 
Intuitive Surgical®.
4
 The same device had been given CE mark approval more than a year 
earlier, in January 1999.
5
 An earlier robot, the AESOP (Automated Endoscopic System for 
Optimal Positioning) System, developed by Computer Motion, had been approved by the 
FDA to assist with surgery in 1994; it used voice recognition to enable the surgeon to control 
the camera for laparoscopic procedures, but it did not perform surgical tasks, such as making 
incisions, dissecting tissue and suturing.
6
 In contrast, the da Vinci® system undertakes all 
these tasks, with instruments held by four robotic arms. The system is controlled by a surgeon 
seated at a console, which can be located remotely from the patient (see Figure 1). Nursing 
staff and anaesthetists, as well as a surgical assistant, stand at the bedside. By default, 
references to robotic surgery in this paper refer to the da Vinci® surgical system, since this is 
the only system on the market after Intuitive merged with its only rival in 2003.
7
   
 
                                                 
4
 US Food and Drug administration (FDA) website, accessed online January 2015. URL: 
http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?ID=K990144. 
5
 Health Information and Quality Authority (HiQA) website, accessed February 2015. URL: 
www.hiqa.ie/system/files/HTA-robot-assisted-surgery.pdf. 
6
 N.G. Hockstein, C.G. Gourin, R. A. Faust,& D. J. Terris. A history of robots: from science 
fiction to surgical robots. Journal of Robotic Surgery 2007; 1: 113-118. DOI: 
10.1007/s11701-007-0021-2.  
7




Figure 1: Surgeon positioned at the control console of the original da Vinci system© 2015, 
Intuitive Surgical, Inc. 
 
To ensure that this article’s scope is manageable within its prescribed length, we focus on one 
application of robotic surgery: prostatectomy. This procedure has had the widest uptake of all 
procedures that have been attempted robotically. As a consequence, the literature and data 
available on outcomes are more extensive than for other robotic procedures. Since the robot 
was first approved for use in urological surgery (2001), uptake for prostatectomy has been 
rapid, particularly in the USA, where features of the predominantly insurance-funded 
healthcare system seem to have facilitated its uptake to the point that robotic procedures now 
account for more than 75% of prostatectomies.
8
 Reasons for this rapid uptake include the 
appeal of laparoscopic techniques for patients (e.g. in view of a speedier recovery), and 
surgeons’ preference for robot-assisted laparoscopic prostatectomy rather than standard 
laparoscopic prostatectomy. From the surgeons’ point of view, the robot simplifies what is 
otherwise a very challenging laparoscopic procedure. Its four arms enable the surgeon to 
control the camera rather than relying on an assistant and make an extra arm available for 
other tools. Other advantages over non-robotic laparoscopic surgery include: increased 
dexterity; resolution of the Fulcrum effect (where the tip of the laparoscopic instrument 
inside the patient moves in the opposite direction to the surgeon’s hand); and incorporation of 
3D vision. Prostatectomy is associated with two side-effects that can seriously compromise 
                                                 
8 M. A. Pilecki, B. B. McGuire, U. Jain, J. Y. S.Kim & R. B. Nadler. National Multi-
Institutional Comparison of 30-Day Postoperative Complication and Readmission Rates 
Between Open Retropubic Radical Prostatectomy and Robot-Assisted Laparoscopic 
Prostatectomy Using NSQIP. J Endourol 2014; 28(4):430-436. Much of the data informing 
this paper is drawn from studies based in the US, due to its high uptake of robotic 
prostatectomy.   
 
 5 
quality of life for the patient– urinary incontinence and impotence. In the 1980s surgeons 
developed new ‘nerve-sparing’ techniques on the basis that damage to a key nerve bundle 
running alongside the prostate was a contributing factor to both these side-effects. The nerve-
sparing procedure is difficult due to the proximity of the nerves, challenges associated with 
the awkward operative field for prostatectomy, and the importance of removing all cancer. As 
a result, incidence of urinary incontinence and impotence after prostatectomy remain high. In 
this context, patients and clinicians are interested in options that improve the chance 
(however slightly) that these side-effects will be avoided. On this basis, there is prima facie 
support for using the robot, since the robot enables scaled down and therefore extremely 
controlled, tiny movements of the surgical instruments. In theory, then, there are a range of 






Justice and innovation 
 
Having described key features of robotic prostatectomy, we now turn to the ethical issues that 
are the focus of this paper: issues concerning justice. In a recent paper in this journal, David 
Hunter identified three types of justice-based objections that can be raised against research 
into radically new technologies: objections based on a lack of procedural justice; objections 
based on an unjust distribution of outcomes at a particular point in time; and objections based 
on outcomes that conform to an unjust pattern of distribution over time.
10
 Hunter emphasized 
the third type of objection, arguing that, when considering the introduction of a radically new 
technology, we should be most concerned when essential features of the new technology are 
likely to preserve and even exacerbate injustice over time. Given this, we examine whether 
there are essential features of surgical innovation that tend to preserve or entrench existing 
patterns of injustice, especially in regard to health outcomes and access to health care.  
 
For our purposes, we do not need to adopt a highly nuanced theory of healthcare justice – 
something more minimal and inclusive will ensure the applicability of our recommendations 
to most contexts in which healthcare justice is considered. The concept we are invoking 
includes concerns for both efficiency and equity.  In the terminology of Cookson and Dolan, 
we invoke a ‘combination principle’, which combines, loosely speaking, ‘maximizing’ and 




Maximizing principles of justice are common in health economics.  These are principles like 
‘allocate resources so as to maximize population health’ or, put differently, ‘allocate 
                                                 
9
 J. Binder & W. Kramer. Robotically-assisted laparoscopic radical prostatectomy. BJU 
International 2001; 87: 408-410. 
10
 D. Hunter. How to object to radically new technologies on the basis of justice: the case of 
synthetic biology. Bioethics 2013; 27(8): 426-34. 
11





resources so as to maximize the number of Quality Adjusted Life Years (QALYs) gained per 
dollar spent’.
12
  We invoke a concept of justice that includes such a concern for population 
health and for some degree of efficiency, and which therefore invites some attention to the 
costs and benefits of different treatments.  We do this for three reasons.  First, it could be 
unjust to expose patients to treatments that cost them more but benefit them less.  Second, it 
could be unjust to stifle a beneficial treatment that comes at no loss to others in terms of 
benefits denied.
13
  Finally, it could be unjust to stifle a greatly beneficial treatment that comes 




Maximizing principles may help to ensure that population health is maximized given 
available resources, but they do not ensure – or aspire to – any degree of equality in the 
distribution of health across the population.  Consequently, theorists may regard maximizing 
principles as fundamentally unrelated to, or even opposed to, concerns for justice.  However, 
Cookson and Dolan,
15
 like Beauchamp and Childress before them,
16
 do talk of maximizing 
principles as principles of justice, namely on the understanding that the ethical question of 
how we ought to allocate resources simply is a question of justice. Turning to the ‘egalitarian’ 
dimension of our conception of justice, we note that Parfit has helpfully distinguished 
‘egalitarian’ approaches, according to which equality is a good thing in itself, from 
‘prioritarian’ approaches, according to which the intuitive appeal of equality really lies in a 
concern about the absolute welfare of individuals, i.e. who is worst off.
17
 Notwithstanding 
their differences, egalitarian and prioritarian approaches both tend to prioritise the people 
worst off. Another approach, sometimes called ‘sufficientism’, proposes that the needs of 
anyone below a certain threshold (of health, wealth, or welfare, for example) should be 
prioritized over the needs of those who meet the threshold.
18
 Proponents of all these 
approaches share a concern for the equal or better-than-equal treatment of those who are 
worst off, at least up to a threshold. 
 
For the purposes of this paper, we propose a minimal conception of justice partly based on 
this common ground: those who are vulnerable, marginalized, or overall worse off should not 
be systematically excluded or disadvantaged in their access to health care or in terms of their 
                                                 
12
 J. Richardson, K. Sinha, A. Iezzi, & A. Maxwell. Maximising health versus sharing: 
measuring preferences for the allocation of the health budget. Soc Sci Med, 2012. 75(8): p. 
1351-61. 
13
 In the economist’s parlance, this is a concern for Pareto-efficiency.   
14
 This equates to a concern to avoid very large opportunity costs. Opportunity costs refer to 
the benefits that must be foregone when resources are allocated to one use and therefore 
cannot be allocated to their next most beneficial use. 
15
 Cookson & Dolan op. cit. note 11. 
16
 T.L. Beauchamp & J.F. Childress. 'Justice', in Principles of Biomedical Ethics. 2009, 
Oxford University Press: Oxford. 
17 D. Parfit. Equality and Priority. Ratio 1997; 10: 202-221. 
18
 See, for example, H. Frankfurt. Equality as a Moral Ideal. Ethics 1987. 98: 21-43; R. Crisp. 
Equality, priority, and compassion. Ethics 2003; 113:745-763; C. Brown. Priority or 
sufficiency …or both? Econ Philos 2005; 21:199-220. 
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health. Thus, we are interested in whether there are any features of surgical innovation that 
would tend to systematically disadvantage those who are already worst off in terms of, for 
example, financial status, geographical location or social group membership. Our conception 
of justice also contains some concern for efficiency, namely whether the costs and benefits 
associated with a treatment justify its being made available to the public and/or subsidized by 
the government.  In the next two sections, we explore these questions at the health system 
level and the individual patient level in light of experiences with robotic prostatectomy. Then, 




Justice issues at the health system level 
 
At the health system level, justice considerations largely relate to ensuring that available 
treatments are safe and effective and that public resources are spent wisely, namely on 
treatments that provide good value for money. Regulatory bodies like the FDA in the US and 
the Therapeutic Goods Administration (TGA) in Australia are responsible for authorizing the 
availability, but not the public subsidy, of new health technologies in the national health 
system.  They serve to protect the public from harm and, to the limited extent to which they 
assess new technologies for efficacy, from financial exploitation subsequent to misleading 
advertising.  In principle, approved products are safe and do what their makers and sellers say 
they do. The regulatory bodies are an important safeguard insofar as they minimize harm 
from unsafe treatment or misleading advertising, but the primary function of these bodies is 
one of market regulation – they authorize marketing and use, leaving questions of value to the 
market or other bodies. 
 
In addition to federal regulatory bodies, welfare states like Australia, the UK and the social 
democracies of Western Europe have further government bodies that evaluate health 
technologies to determine whether they should be publicly subsidized.
19
  (For simplicity, we 
ignore the important role of private health insurers in supporting the development and public 
availability of new technologies.)  These bodies try to strike a balance between maximizing 
population health and ensuring fairness in the allocation of funds across a range of health 
conditions that may disproportionately impact different demographic groups. Such bodies 
may be seen as answering two questions: (1) how should limited resources be allocated 
across disparate areas of health care; and (2) for any given condition, which treatments 
should be publicly funded?  
 
                                                 
19
 We focus on countries with universal health coverage (owing to government subsidies) 
because we would expect justice issues to be least exaggerated in these countries. Thus, if we 
can identify likely justice issues here, then we have reasonable grounds for expecting these 




In practice, however, the first of these questions may not arise explicitly, and may be 
answered solely in answering the second question. Australian funding bodies, for example, 
primarily focus on whether products are clinically effective, and make their funding decisions 
on the expectation that products “of similar clinical effectiveness” will have a similar cost 
(so, conversely, produces of dissimilar effectiveness can have a dissimilar cost).
20
 On this 
basis, the government bodies approve for public funding a wide variety of treatments, 
increasing the choices available to clinicians and patients. Such an approach avoids unfair 
allocation of resources among medical conditions by publicly funding a wide range of 
acceptably effective products for all medical conditions at a dollar rate that compares to 
already funded products. National research priorities in Australia also avoid naming 
particular health conditions, but the most recent priorities list ‘reducing disparities for 
disadvantaged and vulnerable groups’ and ‘better health outcomes for Indigenous people’ 
alongside maximizing principles such as ‘increase efficiency and provide greater value for 
given expenditure’.
21
   
 
This approach is consistent with the principle of justice we are invoking insofar as what 
matters is not purely the aggregate number of health gains achievable under a given resource 
constraint (efficiency), but also the distribution of those gains across the population or, in 
other words, the characteristics of the people to whom the gains accrue (equity).
22
  At the 
health system level, then, a new technology will arguably provide better value for money than 
suggested by its conventional economic evaluation (being focused only on efficiency) if 
publicly subsidizing the technology will: help the worst off, even if only by a small margin; 
help people to reach their potential for health gain, even if this health gain is small in absolute 
terms (for instance, due to intractable disability or co-morbidity); help to reduce unjust health 
                                                 
20
 This wording comes from the Australian Government Department of Health and Aging. 




 Australian Government. Science and Research Priorities and Practical Research Challenges 





 See, for example, A. Wagstaff, 1991. QALYs and the equity-efficiency trade-off. J Health 
Econ 10:21-41.; O. F. Norheim, M. Johri, D. Chisholm, E. Nord, R. Baltussen, D.W. Brock, 
P. Carlsson, R. Cookson, N. Daniels, M. Danis, M. Fleurbaey, K.A. Johansson, L. Kapiriri, P. 
Littlejohns, T. Mbeeli, K.D. Rao, T. Tan-Torres Edejer, and D. Wikler.  Guidance on Priority 
Setting in Health Care (GPS Health). In PRIORITIES 2012: Partnerships for Improving 
Health Systems. Vancouver: International Society on Priorities in Health Care; J. McKie & J. 
Richardson. 2005. Neglected equity issues in cost effectiveness analysis – part 1: severity of 
pre-treatment condition, realisation of potential for health, concentration and dispersion of 
health benefits, and age-related social preferences. Monash University, Centre for Health 
Economics; A. J. Culyer, & A. Wagstaff. 1993. Equity and equality in health and health care. 
J Health Econ 12 (4):431-57; A. J. Culyer, 2001. Equity – some theory and its policy 
implications. J Med Ethics 27 (4):275-83. 
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inequalities, such as inequalities associated with morally irrelevant characteristics like socio-
economic status, gender and area of living; help to protect people’s workforce productivity or 





In light of the above, it is important to consider health system level questions about who 
benefits from publicly subsidized prostatectomy. Does prostate cancer disproportionately 
affect some social groups, and does this raise any questions of justice? There is some 
evidence that prostate cancer does affect different racial groups differently. For example, 
African-American men suffer from higher rates of prostate cancer than other racial groups, 
and these cases of cancer occur in younger individuals and more commonly result in death.
24
 
It is likely that a number of factors contribute to this phenomenon; these are likely to include 
both genetic and socio-economic factors, since the disparity persists in groups with equal 
income and access to healthcare.
25
 If evidence of this phenomenon is accepted, then the fact 
that prostate cancer has a disproportionate impact on members of a marginalized group might 
be a reason to prioritize its treatment, with particular emphasis on the accessibility of gold-
standard treatment to the disproportionately affected group. 
 
Another social dimension arises because prostate cancer is only suffered by men, and as such 
its treatment may arguably be associated with gender biases. For example, many innovations 
in prostate cancer care focus on reducing side-effects of treatment, such as impotence; and 
while male sexual function is an important thing to preserve, there is arguably a risk of 
valuing this too highly in a patriarchal society and a male-dominated medical establishment. 
It is important to ensure that gender bias does not lead to the disproportionate public subsidy 
of a treatment offering marginal or merely perceived improvements in outcomes associated 
with male sexual function, namely over other candidates for funding that may offer greater 
benefits, such as breakthroughs in cancer treatment or improved treatments for conditions 
suffered by a larger patient cohort. 
 
A key component of value for money, especially when resources are limited, concerns how 
much it costs to achieve the additional health benefits made possible by a new technology 
over its comparator (e.g. an older, rival technology). New technologies tend to be both more 
                                                 
23
 O. Norheim, M. Johri, D. Chisholm, E. Nord, R. Baltussen, D. Brock D et al. 
2012.Guidance on Priority Setting in Health Care (GPS Health).  In PRIORITIES 2012: 
Partnerships for Improving Health Systems. 2012, International Society on Priorities in 
Health Care: Vancouver: doi:10.1186/1478-7547-12-18  
24
 F. T. Odedina, T. O. Akinremi, F. Chinegwundoh, R. Roberts, D. Yu, R. R. Reams, M. L. 
Freedman, B. Rivers, B. L. Green & N. Kumar. Prostate cancer disparities in Black men of 
African descent: a comparative literature review of prostate cancer burden among Black men 
in the United States, Caribbean, United Kingdom, and West Africa. Infectious Agents and 
Cancer 2009; 4 :S2 doi: 10.1186/1750-9378-S1-S2.;  
25
 T. S. Wells, A. T. Bukowinski, T. C. Smith, B. Smith, L. K. Dennis, L. K. Chu, G. C. Gray 
& M. A. K. Ryan Margaret. Racial Differences in Prostate Cancer Risk Remain Among US 
Servicemen With Equal Access to Care. The Prostate, 2010; 70: 727-734. 
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effective but also more costly, so the question then arises as to whether the additional effects 
are worth the additional costs. However, this is an oversimplification of the assessment 
required, because new technologies may be more effective in the future even if they are not 
initially more effective, and they may be more affordable in the future even if they are not 
initially more affordable.  Government bodies must consider the opportunity cost of publicly 
subsidizing a new technology by, in effect, asking whether the public will be better off if the 
new technology is subsidized or if the resources needed for this are instead expended 
differently, for example, on an older, rival technology. In assessing whether a treatment such 
as robotic prostatectomy represents value for money, it is important to consider both its costs 
and outcomes. In what follows, we discuss each of these in turn. 
 
While estimates of the cost of a robotic prostatectomy vary, it seems fair to say that there are 
cheaper ways of treating prostate cancer. Both of the alternative surgical treatments – open 
prostatectomy and laparoscopic prostatectomy – are less expensive, even accounting for the 
cost of the extra days in hospital for the open procedure.
26
  The comparison of costs is further 
complicated by the availability of non-surgical therapies such as Cryoblation (localized 
freezing) and Brachytherapy (internal radiotherapy),
27
 while in some cases of early prostate 




Of course, costs can change over time, altering whether or not a procedure is cost-effective. 
For instance, one of the reasons robotic surgery is currently expensive is because there is a 
monopoly. If other companies were to develop and get approval for similar devices, increased 
competition might lead to lower costs for buyers and users. Increased uptake can also lead to 
reduced costs, as mass production reduces costs by increasing the efficiency of production 
and distribution. However, it is difficult to see how the cost of a robotic system plus 
associated laparoscopic instruments could ever be less than the cost of laparoscopic 
instruments without the robot, or indeed the scalpel and other simple instruments required for 
open surgery. The robot replaces neither the tools, nor the surgeon (who is still required to 
operate the robot), so there is no obvious potential for cost saving in terms of the equipment. 
Furthermore, while laparoscopic surgery reduces the cost of the hospital stay compared to 
open surgery (due to reduced surgical wound and blood loss), robotic surgery may not offer 
                                                 
26
 Y. Lotan. Is robotic surgery cost effective: no. Curr Opin Urol 2012; 22:66-69; R. M. Hall, 
N. Linklater & G. Coughlin. Robotic and open radical prostatectomy in the public health 
sector: cost comparison. ANZ Journal of Surgery 2013; 84:477-480; S. L. Chang, A. S. Kibel, 
J. D. Brooks & B. I. Chung. The impact of robotic surgery on the surgical management of 
prostate cancer in the USA. BJU International 2014; Online Early View. DOI: 
10.1111/bju.12850. 
27
 J. B. Malcolm, M. D. Fabrizio, B. B. Barone, R. W. Given, R. S. Lance, D. F. Lynch, J. W. 
Davis, M. E. Shaves & P. F. Schellhammer. Quality of Life After Open or Robotic 
Prostatectomy, Cryoblation or Brachytherapy for Localized Prostate Cancer. J Urol 2010; 
183: 1822-1829. 
28
A. Bill-Axelson, L. Holmberg, M. Ruutu, H. Garmo, J. R. Stark, C. Busch, S. Nordling, M. 
Häggman, S. – O. Andersson, S. Bratell, A. Spångberg, J. Palmgren, G. Steineck, H.- O. 
Adami, J. – E. Johansson. Radical Prostatectomy versus Watchful Waiting in Early Prostate 
Cancer. New Engl J Med 2011; 364: 1708-1717. 
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even these advantages over standard laparoscopic surgery. Nor does robotic surgery currently 





Alongside costs, another factor central to the value for money offered by a procedure lies in 
the quality of its outcomes. It is difficult to know whether the robot offers sufficiently better 
outcomes to represent value for money, due to limitations of the current evidence. 
 
When comparing the outcomes of treatments for prostate cancer, there are three different sets 
of outcomes to take into account, with different levels of importance: the cancer-related 
outcomes, the rates of serious or long-term complications, and short-term or less serious 
complications. Cancer-related outcomes are most important insofar as the motivation for 
prostatectomy is to cure prostate cancer and thereby prolong life. Cancer-related outcomes 
include margin clearance rates, prostate-specific antigen (PSA) levels, subsequent cancer 
treatments required, and mortality from prostate cancer. Most of the published research 
suggests that robotic surgery is comparable to open and standard laparoscopic surgery in 




Cancer-related outcomes aside, there are two common and undesirable long-term, potentially 
permanent side-effects associated with prostatectomy: incontinence and impotence.
31
 A 2005 
                                                 
29
 C. Bolenz, S. J. Freedland, B. K. Hollenbeck, Y. Lotan, W. T. Lowrance, J. B. Nelson & J. 
C. Hu. Costs of Radical Prostatectomy for Prostate Cancer:  A Systematic Review.  Europ 
Urol 2014 ; 65: 316-324. 
30
 W. T. Lowrance, E. B. Elkin, L. M. Jacks, D. S. Yee, T. L. Jang, V. P. Laudone, B. D. 
Guillonneau, P. T. Scardino & J. A. Eastham. Comparative Effectiveness of Prostate Cancer 
Surgical Treatments: A Population Based Analysis of Postoperative Outcomes. J Urol 2010; 
183: 1366-1372.; M. Alemozaffar, M. Sanda, D. Yecies, L. Mucci, M. J. Stampfer & S. A. 
Kenfield. Benchmarks for Operative Outcomes of Robotic and Open Radical Prostatectomy: 
Results from the Health Professionals Follow-up Study. Europ Urol 2014 (in press, online 
early). http://dx.doi.org/10.1016/j.eururo.2014.01.039.; G. Gandaglia, F. Abdollah, J. Hu, S. 
Kim, A. Briganti, J. D. Sammon, A. Becker, F. Roghmann, M. Graefen, F. Montorsi, P. 
Perrotte, P. I. Karakiewicz, O.-D. Trihn & M. Sun. Is Robot-Assisted Radical Prostatectomy 
Safe in Men with High-Risk Prostate Cancer? Assessment of Perioperative Outcomes, 
Positive Surgical Margins and Use of Additional Cancer Treatments” J Endourol 2014; 
28(7):784-791. There is one recent systematic review that suggests a slight advantage for 
robotic prostatectomy in terms of margin clearance, although the authors note that the 
evidence informing the review has limitations due to the lack of randomized studies. (See A. 
Tewari, P. Sooriakumaran, D. A. Bloch, U. Seshadri-Kreaden, A. E. Hebert & P. Wiklund. 
Positive Surgical Margin and Perioperative Complication Rates of Primary Surgical 
Treatments for Prostate Cancer: A Systematic Review and Meta-Analysis Comparing 
Retropubic, Laparoscopic, and Robotic Prostatectomy. Europ Urol 2012; 62:1-15). 
31
 Continence has the greatest impact on quality of life assessments following prostatectomy, 
and is therefore regarded as the next most important outcome after cancer-related outcomes. 
See, for example, A. Sood, W. Jeong, J. O. Peabody, A. K. Hemal & M. Menon. Robot 
Assisted Radical Prostatectomy: Inching Toward Gold Standard. Urol Clin N Am 2014; 41: 
473-484, p. 476. 
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study with five year follow up showed that whereas 87% of participants had total urinary 
control prior to prostatectomy, the percentage with full urinary control after the procedure 
peaked at 39%. The same study found that whereas 81% of participants were able to achieve 
erections firm enough for intercourse prior to their prostatectomy, the number who were able 
to achieve this after the procedure peaked at 28%.
32
 The likelihood of these side-effects 
occurring, particularly impotence, is dependent on a range of factors, including tumor size 
and location, and patient age, which makes comparison of surgical approaches more 
challenging. In theory, the high degree of control and the ability to scale down the 
movements of the instruments, as well as to eliminate any effects of hand wobble, give 
robotic surgery an advantage over open or laparoscopic surgery in terms of achieving margin 
clearance while sparing the nerves associated with continence and sexual function. 
Furthermore, the 3D camera gives an in-principle advantage to robotic surgery over standard 
laparoscopic surgery in terms of an enhanced view of the operative field. Some studies 
appear to confirm this in-principle advantage, showing slightly better outcomes for the 
robotic procedure,
33




The third set of surgical outcomes concern recovery time and blood loss. We take these to be 
of lower importance than cancer-related outcomes, continence and sexual function, because 
they do not generally have significant long-term implications for the patient (although blood 
loss sometimes results in a blood transfusion and its associated risks). Studies consistently 
show that the robotic procedure is associated with reduced blood loss and a significantly 
shorter hospital stay compared to open prostatectomy (e.g. Lowrance et al. found a 35% 
shorter stay with laparoscopic treatment compared to open surgery).
35
  These differences are 
to be expected in any minimally invasive surgery, since they primarily relate to the smaller 
incision size required – blood loss and length of hospital stay are largely determined by the 
surgical wound. There is also some evidence that robotic surgery may offer a small advantage 
over standard laparoscopic surgery for blood loss and hospital stay.
36
 While a reduction in 
wound size and associated morbidity are of less importance than treatment effectiveness, and 
generally do not have an impact on long-term outcomes, such factors would come into play in 
assessing comparative effectiveness, and therefore cost-effectiveness, if the treatment options 
were otherwise equivalent. 
 
                                                 
32
 Note that for sexual function the percentage able to achieve erections firm enough for 
intercourse was highest at 60 months follow up, whereas for urinary continence the 
percentage with full control was highest at 24 months follow up. This data is from D. F. 
Penson, D. McLerran, Z. Feng, L. Li, P. C. Albertsen, F. D. Gilliland, A. Hamilton, R. M. 
Hoffman, R. A. Stephenson, A. L. Potosky & J. L. Stanford. 5-Year Urinary and Sexual 
Outcomes After Radical Prostatectomy: Results from the Prostate Cancer Outcomes Study J  
Urol 2005; 173:1701-1705. 
33
 A. Tewari et al. op. cit. note 30. 
34
 M. Alemozaffar et al. op. cit. note 30.; G. Gandaglia et al. op. cit. note 30. 
35
 W. T. Lowrance et al. op. cit. note 30. 
 G. Gandaglia et al. op. cit. note 30.  
36
 A. Tewari et al. op. cit. note 30, p. 13. 
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It is obvious from the above that limitations in the evidence available pose a challenge for 
assessing the overall benefits, and therefore the cost-effectiveness, of robotic surgery.  These 
are left uncertain, and high levels of uncertainty rightly increase a government’s hesitation to 
publicly subsidize an intervention, in effect reducing its perceived value for money.  This is 
explicitly stated in the funding policies of Australia and comparable countries.
37
   
 
These limitations in the evidence on the safety and effectiveness of robotic prostatectomy are 
likely to translate to other surgical innovations, as they are at least partly a result of 
difficulties in evaluating surgical interventions.
38
 The pattern of diffusion for surgical 
innovations is such that evidence about comparative effectiveness is often available only after 
the technology is well-established, and randomized trials may never be undertaken due to 
practical challenges.
39
 This in turn means that the uptake of often expensive treatment with 
dubious advantages over conventional treatment is likely to be relatively widespread in 
surgery.  Another complication arises due to the likelihood that the results from early studies 
are confounded by the impact of the learning curve, since there is evidence that surgeons’ 
outcomes continue to improve after performing more than 100 procedures.
40
 Refinement of 
the equipment and technique may also mean that outcomes for later patients are better than 
those for the first patients.
41
 Should we accept the methodological difficulties of producing 
high-quality evidence in the case of surgical interventions, and accordingly subject surgical 
interventions to lower standards of evidence?  Rogers and co-authors have clearly and 
persuasively argued ‘no’.
42
 So, there is an important question of what to do. Staged 
approaches to treatment introduction and evaluation, as proposed by the authors of the 
                                                 
37 Australian Government Department of Health and Ageing. Proposal for changes to the 
Medical Services Advisory Committee (MSAC) processes for applications for public funding, 
Australian Government: Canberra 2010; Australian Government Department of Health and 
Ageing, Guidelines for preparing submissions to the Pharmaceutical Benefits Advisory 
Committee. Australian Government: Canberra 2008; Scottish Medicines Consortium, 
Guidance to Manufacturers for Completion of New Product Assessment Form (NPAF). 
Glasogow 2013; National Institute for Health and Care Excellence, Guide to the methods of 
technology appraisal 2013, in Process and methods guides. 2013.; National Institute for 
Health and Care Excellence, Diagnostics assessment program manual. 2011.; and Canadian 
Agency for Drugs and Technologies in Health (CADTH), Guidelines for the Economic 
Evaluation of Health Technologies: Canada. 2006: Ottawa. 
38
 P. L. Ergina, J. A. Cook, J. M. Blazeby, I. Boutron, P. A. Clavien, B. C. Reeves  & C. M.  
Seiler. (2009) Challenges in evaluating surgical innovation. Lancet 2009; 374: 1097-1104. 
39
 P. L. Ergina, J. S. Barkun, P. McCulloch, J. A. Cook & D. G. Altman., IDEAL framework 
for surgical innovation 2: observational studies in the exploration and assessment stages. BMJ 
2013; 346:f3011. 
40
 N. L. Sharma, A. Papadopoulos, D. Lee, J. McLoughlin, S. L. Vowler, H. Baumert, A. Y. 
Warren, V. Patil, N. Shah & D. E. Neal. First 500 cases of robotic-assisted laparoscopic 
radical prostatectomy from a single UK centre: learning curves of two surgeons” BJU 
International 2010; 108: 739-748. 
41
 Some refinements are described in Sood et al. op. cit. note 31. 
42
 W. Rogers, C. Degeling & C. Townley. Equity under the knife: justice and evidence in 
surgery. Bioethics 2014; 28(3): p. 119-26. 
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A final set of considerations that are arguably relevant to justice, but may not 
straightforwardly reduce to cost-effectiveness or equity, are the preferences of patients and 
surgeons. These preferences are sometimes motivated by aesthetic considerations or 
convenience, but for particular patients, such as those who are older, physically weaker or 
with compromised immune systems, the choice of a minimally invasive procedure might be 
clinically indicated.
44
 Publicly funding a variety of treatment modalities supports equity by 
making appropriate interventions available to particular individuals for whom they are 
clinically indicated. Surgeon preference may also be relevant to questions of justice insofar as 
the technical difficulty of standard laparoscopic prostatectomy prevents many surgeons from 
taking it up despite patient demand. Sundi and Han note that “robotic assistance has rendered 
minimally invasive radical prostatectomy technically feasible for many surgeons, whereas 
laparoscopic prostatectomy without robotic assistance is technically daunting and has a steep 
learning curve”. They go on to suggest that robotic surgery “has significant merit as an 
enabling technology.”
 45
 This claim is supported by the trend for recent comparative studies 
to omit non-robotic laparoscopic prostatectomy on the basis that it is now rarely performed – 




The above reflections on justice at the health system level will play an important role in 
informing our recommendations regarding surgical innovation. However, despite limited 
evidence that public subsidy of robotic prostatectomy will improve prostate cancer outcomes 
                                                 
43
 P. McCulloch, J. A. Cook, D. G. Altman, C Heneghan & M. K. Diener . IDEAL 
framework for surgical innovation 1: the idea and development stages. BMJ 2013; 
346:f3012.; Ergina et al. op. cit. note 39; and J. A. Cook, P. McCulloch, J. M. Blazeby, D. J. 
Beard, D. Marinac-Dabic & A. Sedrakyan. IDEAL framework for surgical innovation 3: 
randomized controlled trials in the assessment stage and evaluations in the long term study 
stage. BMJ 2013; 346:f2820. 
44
 In the case of robotic prostatectomy, however, it is not clear whether patient preferences 
are driven by such considerations, or by the widespread perception that robotic surgery is 
associated with better outcomes than other treatment options. This perception may be 
encouraged by claims made in mainstream media and on hospital websites, as reported in S. 
Alkhateeb & N. Lawrentschuk. Consumerism and its impact on robotic-assisted radical 
prostatectomy.  BJU International 2011; 108: 1874-1878. 
45
 D. Sundi &  M. Han. Limitations of Assessing Value in Robotic Surgery for Prostate 
Cancer: What Data Should Patients and Physicians Use to Make the Best Decision?. Journal 
of Clinical Oncology 2014. Available online before print. Accessed January 2015 doi: 
10.1200/JCO.2013.54.9741 This quote p. 1394. 
46
 See, for example, M. A. Pilecki, B. B. McGuire, U. Jain, J. Y. S. Kim John & R. B. Nadler 
National Multi-Institutional Comparison of 30-Day Postoperative Complication and 
Readmission Rates Between Open Retropubic Radical Prostatectomy and Robot-Assisted 
Laparoscopic Prostatectomy Using NSQIP. J Endourol 2014; 28 (4): 430-436.  In another 
article (T. J. Vidovszky, W. Smith, J Ghosh & M. R. Ali. Robotic Cholecystectomy: Learning 
Curve, Advantages and Limitations. J Surgl Res 136: 172-178) the authors note the 
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or reduce associated inequities, and despite its higher cost, it appears that increased uptake by 
health systems is inevitable. In Australia, robotic prostatectomy is already subsidized by the 
government through Medicare as a form of ‘prostatectomy’, although only at the same rate as 
open and laparoscopic procedures.
47
 And while robotic prostatectomy is not yet widely 
available within the public health system – most da Vinci robots are currently owned by 
private hospitals – the recent acquisition of a da Vinci robot by the New South Wales (NSW) 
state government makes robotic surgery available for the first time to public patients in that 
state. In a press release, the NSW Minister for Health declared that “[r]obotic-assisted 
surgery is the next phase in the evolution of healthcare and I am delighted that it will improve 
clinical care for those public patients requiring surgery”.
48
 The Minister’s words echo Sundi 
and Han’s recent observation that when it comes to robotic prostatectomy we “are truly in the 
[…] postdissemination era. Whether it will become widely adopted is no longer in question – 
despite increased costs, it already has.” Once an innovative treatment has been adopted, a 
different set of justice questions arise. These questions relate to whether individual patients 
have equitable access.  
 
 
Justice issues at the patient level 
 
There is evidence that access to robotic prostatectomy is not currently distributed based 
purely on morally relevant characteristics such as medical necessity or the capacity to benefit 
from treatment. Research from the US shows that individuals from minority or disadvantaged 
backgrounds (African American, Hispanic and lower socio-economic patients) do not access 
robotic surgery in the same relative proportions as Caucasian men of higher socio-economic 
status.
49
  This may be particularly concerning in the case of African American men, who tend 
to have prostate cancers with a younger onset and worse prognosis.
50
 There are also issues of 
justice on geographical grounds, with evidence that robotic surgery is offered more 
frequently in teaching hospitals than non-teaching hospitals, more in urban areas than rural 
ones, and that patients on average need to travel further to access robotic surgery, thereby 
                                                 
47
 Radical prostatectomy is refunded under Medicare Benefits Scheme codes 37210 and 
37211 irrespective of whether it is an open, standard laparoscopic, or robotic procedure. See 
Medicare Benefits Schedule Online: 
http://www9.health.gov.au/mbs/search.cfm?q=37210%2C37211&sopt=I (accessed January 
2015) 
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49
 S. P. Kim, S. A. Boorjian, N. D. Shah, C. J. Weight, J. C. Tilburt, L. C. Han, R. H. 
Thompson, Q. – D. Trinh, M. Sun, J. P. Moriarty & R. J. Karnes. Disparities in Access to 
Hospitals with Robotic Surgery for Patients with Prostate Cancer Undergoing Radical 
Prostatectomy. J Urol 2013; 189: 514-520. 
50
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Hunter rightly urges caution when considering whether injustices associated with innovative 
treatments early on are likely to become entrenched.
52
 It is inevitable, for example, that a new 
surgical treatment will initially be available in a limited number of treatment centres. There 
are, however, some features of surgery that might increase the likelihood of entrenched 
injustice. Unlike most new pharmacological agents, the volume of cases encountered is 
relevant for skills acquisition and skills maintenance in surgery. Surgery has learning curves 
such that the more a procedure is performed both by an individual surgeon and by a surgical 
team, the better their proficiency and outcomes will be.
53
 This explains the results of a 
number of studies that show better outcomes for early robotic prostatectomy procedures when 
performed by higher-volume surgeons and at higher-volume centres. Given the link between 
high throughput and better outcomes, it seems there might be (understandable) pressure for 
the procedure to be undertaken, particularly early in its development, by just a few surgeons 
and teams at busier, more centrally located hospitals, with implications for justice in terms of 
which patients access these hospitals. However, this issue is not only associated with new 
procedures during the learning curve. There is strong evidence that surgical outcomes are 
better when surgeons, surgical teams, and institutions have higher volumes of the procedure 
in question, even after learning curves have been overcome. Thus consideration of likely 
ongoing volume of robotic procedures will result in pressure to centralize robotic surgery, 
and to limit the number of hospitals where it is practiced. In the US, where uptake is higher 
than in Australia and the UK, there is evidence that some populations are more proximate to 
hospitals offering robotic surgery (either because they live closer, or because they have better 
access to the transport and other supports that make traveling for surgery a viable option).
54
 
In Australia, uptake is in its early stages, so it is inevitable that services are currently located 
at only a few major hospitals. However, it is likely that the geographical location of robotic 
surgery will entrench these geographical inequities. It is important to be particularly mindful 
of this in countries such as Australia, where the concentration of Indigenous populations and 
people of lower socio-economic status is higher in regional communities. 
 
There are other related factors which contribute to patients being selected for robotic 
prostatectomy on grounds that are not morally relevant. These involve the cost of the robot, 
both in terms of the initial outlay and the ongoing use and maintenance. Hospitals with a 
robot need to use it regularly to improve its cost-effectiveness, since the robot is expensive to 
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 Hunter, op. cit. note 10. 
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 There is some disagreement over the duration of the learning curve. However, for robot-
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procedures. See, for example Sharma et al., op. cit. note 40. 
54
 Kim et al., op. cit. note 49. 
 
 17 
maintain. This may lead to pressure to maximize its value, which poses a number of potential 
risks for patients. First, there may be a widening of indications for robotic prostatectomy, 
where an alternative surgery or non-surgical intervention might otherwise be preferable.
55
 
Although widening indications represents value for money through maximizing the use of the 
equipment, doing so is not warranted if the cost is still higher in absolute terms or if an 
alternative treatment would have been safer or more effective for the patient. In treating 
prostate cancer there are alternatives to surgery and surgery is not the best choice for all 
patients. Malcolm et al. compared prostatectomy with two non-surgical approaches and found 
that, for localized prostate cancer, the non-surgical interventions were associated with better 
quality-of-life scores and statistically similar scores for margin clearance compared to any 
surgical approach.
56
 In addition, Bill-Axelson et al. compared prostatectomy with watchful 
waiting and their subgroup analysis suggested that surgery may be no better than watchful 
waiting in men over 65.
57
 Furthermore, in the case of technology that has other applications, 
as the robot does, its use might be further extended to treat additional conditions. Again, 
though the robot might be operating more cost-effectively with more frequent use, and might 
benefit the patients it is used on, this is only desirable if robotic surgery is an appropriate and 
cost-effective intervention compared to alternatives.    
 
We are not suggesting any intentional or deliberate strategy on the part of surgeons, hospitals 
or policy makers to discriminate against patients from particular groups or locations. 
However, in effect certain patients may be adversely and unfairly impacted by the reality of 
how the robot has diffused into practice. To recall Hunter’s distinctions, this comprises a 





Justice and innovative surgery – recommendations 
 
Based on our analysis, there are a number of important considerations for policy makers 
when introducing new surgical interventions, particularly those associated with expensive 
technology. At the health system level, it is necessary for decision makers to consider the 
following questions before funding new surgical interventions, particularly interventions 
based on expensive technology: 
 
1. Who will benefit from the introduction of this procedure? Do those who benefit fall 
disproportionately within one or more social groups (e.g. based on gender, race, 
class)? Are those groups already better or worse off? 
2. What is the expected degree of benefit to the patient, and is it temporary (e.g. faster 
recovery time) or ongoing (e.g. better cancer survival rates)? 
                                                 
55
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3. How important is the benefit, both to individual patients (e.g. in terms of surgical 
outcomes) and to society (e.g. in terms of productivity and quality of life measures)? 
4. What are the possible future benefits, particularly in terms of foreseeable refinement 
of the procedure? 
5. In view of all of the above, is the procedure cost-effective, and what is its potential to 
compound or, conversely, alleviate extant injustices, namely in how social goods are 
distributed over time? 
 
Based on these questions, decision makers will glean some sense of the innovation’s 
implications for justice in the healthcare system as a whole. Answering these questions will 
involve analyzing cost-effectiveness as well as dimensions of inclusion – that is, considering 
the distribution of benefits and risks, particularly as these impact members of marginalized 
groups. We further recommend that decision makers adopt a framework for the ongoing 
evaluation of the effectiveness of innovative surgical procedures, such as the IDEAL model 
proposed by the Balliol collaboration.
59
 Decisions about diffusion and funding should 
continue to be sensitive to the growing body of evidence about the effectiveness of the 
procedure and associated risks. 
 
Furthermore, our analysis suggests that even if the system-level analysis is favourable, 
surgical innovation is associated with a set of challenges to justice at the individual patient 
level. Because surgical interventions need to be provided at a set location by a specialist, they 
are not equally accessible to all patients. Some patients may need to travel or arrange care 
and support for themselves or their dependents in order to obtain treatment. This issue is 
compounded by the importance of ensuring sufficient patient volumes are maintained by 
surgeons and centres, because a negative correlation between volume and poor outcomes has 
been demonstrated for many surgical interventions. In the case of very expensive technology, 
such as robotic surgery, these issues are further compounded – even if volume requirements 
could be met with widely diffused technology, cost-effectiveness considerations might warn 
against broader dispersal of such technology. 
 
Given this potential source of entrenched injustice, we recommend that the introduction of 
innovative surgical interventions, particularly those associated with high-cost technology 
such as the robot, is accompanied by a plan and funding to maximize equity of access for 
those who are located far afield. Use of this funding should not be narrowly constrained – the 
funding should be available to patients to meet any of the needs arising from the necessity of 
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In this paper we have used the case of robotic prostatectomy to explore the implications of 
surgical innovation for justice in healthcare. We have identified a number of factors 
associated with surgical innovation that raise challenges for justice at the health system level 
and at the individual patient level. At the health system level, we note that surgical innovation 
is often diffused ahead of high-quality evidence of effectiveness, and that early evidence may 
be compromised by the learning curve. Nonetheless, evidence of benefits to patients must be 
considered, alongside reflection on the importance of those benefits. Benefits to surgeons 
(such as comfort, safety or ease of use) might also be relevant, especially where they enable 
surgeons to take clinical indications of the particular patient, and patient preferences into 
account. Furthermore, it is important for decision makers to consider whether members of 
marginalized groups are likely to be under or over-represented in the treatment population. 
These factors should be weighed against the expected cost of diffusing the treatment, 
especially via public subsidy. 
 
Once a treatment is made widely available (e.g. through public subsidy or mandated private 
insurance coverage), surgical innovations are often associated with further problems 
concerning justice at the level of individual patients. Surgical innovations, particularly those 
associated with difficult procedures and procedures requiring expensive technologies, often 
need to be centralized in order to maximize cost-effectiveness and achieve the best possible 
outcomes. This can lead to injustice for patients who are not located near these centres, and 
the patients affected are likely to disproportionately include Indigenous populations and 
patients of lower socio-economic status. Therefore, we also recommend that new surgical 
interventions are accompanied by funding to eliminate, or at least ameliorate, these sources of 
injustice, particularly funding for travel, accommodation and the support of carers. The cost 
of such justice-oriented support services ought to be incorporated into the funding package 
and projections for the new treatment. Surgical innovation has the potential to contribute to 
patient longevity and enhanced quality of life, but we ought to ensure that these benefits are 
justly distributed. 
 
 
